
Congress Members Urge Attorney General to Reject Cannabis Rescheduling to Schedule III
Key Takeaways
- Congress members oppose cannabis rescheduling, citing addiction risks, lack of medical value, and potential health issues like psychosis and anxiety.
- Rescheduling could imply cannabis is harmless, benefiting illegal businesses with tax breaks and posing risks to children.
Citing risks to children, health, and public safety, nine Congress members sent a letter to Attorney General Pam Bondi and President Donald Trump, opposing the rescheduling of cannabis.
In late August, multiple members of Congress sent a
The letter, dated August 28, 2025, references the recommendation from the Food and Drug Administration in 2024 to reschedule cannabis from its current position as a Schedule I substance according to the Controlled Substances Act (CSA), to Schedule III.
President Donald Trump is also cc’d on the letter. In August, President Trump had stated the
What are the main arguments against cannabis rescheduling?
The main arguments in the letter focus on:
- The CSA system of scheduling. Cannabis has a risk for addiction and has no medical value, the letter states, citing studies on cannabis and associations with psychosis, anxiety, and other conditions, as well as the risks for stroke and heart attack.
- The potential tax breaks for illegal businesses. The letter argues that tax code 280E prevents illegal businesses and drug cartels from collection billions of dollars in tax write offs.
- The risk of harm to children. Rescheduling would send the message that cannabis does not cause harm.
The letter also argued that medical and recreational cannabis are the same due to the lack of distribution in dispensaries by budtenders rather than pharmacies, further stating that smoking cannabis is not medical cannabis, due to the carcinogenic risks. It also cited a study that suggested smoking cannabis could worsen PTSD symptoms among veterans.
It also mentioned the
What Did the Congresspeople Say?
In an August 28 press release regarding the letter to Attorney General Bondi,
Congressman Paul Gosar is also quoted in the press release and signed the letter, though on August 21, 2025,
Nine signatures end the letter, including a signature from Congresswoman Mary Miller. In 2024, Miller had
One day after the letter to Attorney General Bondi was published,
References
- Congressman Pete Sessions. Letter to Attorney General Pam Bondi
https://sessions.house.gov/_cache/files/7/b/7beeb164-2110-4c13-aa51-0c0492197a69/1863D148AC9A0301BE40DD60390CA7D04B5816E946BE57072C24DAE317F8FBC7.letter-to-doj-re.-congressional-opposition-to-marijuana-rescheduling.pdf (accessed Sept 8, 2025). - McEvoy, E. Trump Administration Examining Possibility of Cannabis Rescheduling
https://www.cannabissciencetech.com/view/trump-administration-examining-possibility-of-cannabis-rescheduling (accessed Sept 8, 2025). - Colli, M. Southern California ICE Raids Targeting Cannabis Nurseries Trigger Protests
https://www.cannabissciencetech.com/view/southern-california-ice-raids-targeting-cannabis-nurseries-trigger-protests (accessed Sept 8, 2025). - Congressman Pete Sessions. Congressman Sessions Leads Letter Opposing Marijuana Rescheduling
https://sessions.house.gov/2025/8/congressman-sessions-leads-letter-opposing-marijuana-rescheduling (accessed Sept 8, 2025). - Congressman Paul Gosar. Rescheduling Weed is Bad for Wellness and Bombs Politically
https://gosar.house.gov/news/documentsingle.aspx?DocumentID=9002 (accessed Sept 8, 2025). - McEvoy, E. Amendment to 2024 Farm Bill Draft Would Affect Intoxicating Hemp-Derived Products
https://www.cannabissciencetech.com/view/amendment-to-2024-farm-bill-draft-would-affect-intoxicating-hemp-derived-products (accessed Sept 8, 2025). - Colli, M. The Reintroduced MORE Act: Is Federal Cannabis Legalization Finally on the Horizon?
https://www.cannabissciencetech.com/view/the-reintroduced-more-act-is-federal-cannabis-legalization-finally-on-the-horizon- (accessed Sept 8, 2025).
Newsletter
Unlock the latest breakthroughs in cannabis science—subscribe now to get expert insights, research, and industry updates delivered to your inbox.





